Get the Stockscreener App
7.74
0.90%
-0.07
After Hours:
7.77
0.03
+0.39%
Arvinas Inc stock is traded at $7.74, with a volume of 1.20M.
It is down -0.90% in the last 24 hours and up +13.99% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.81
Open:
$7.82
24h Volume:
1.20M
Relative Volume:
0.68
Market Cap:
$568.25M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.6574
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-1.15%
1M Performance:
+13.99%
6M Performance:
-14.29%
1Y Performance:
-68.42%
1-Day Range:
$7.56
$7.855
1-Week Range:
$7.56
$8.2256
52-Week Range:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.74 | 574.86M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas, Inc. $ARVN Shares Acquired by Edmond DE Rothschild Holding S.A. - MarketBeat
Alyeska Investment Group L.P. Acquires New Position in Arvinas, Inc. $ARVN - MarketBeat
Invesco Ltd. Acquires 44,493 Shares of Arvinas, Inc. $ARVN - MarketBeat
What’s the RSI of Arvinas Inc. stock2025 Top Decliners & Low Risk High Win Rate Picks - Lancaster City Council
Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified - simplywall.st
Philosophy Capital Management LLC Takes $6.99 Million Position in Arvinas, Inc. $ARVN - MarketBeat
ADAR1 Capital Management LLC Acquires Shares of 313,354 Arvinas, Inc. $ARVN - MarketBeat
Arvinas, Inc. $ARVN Shares Acquired by Graham Capital Management L.P. - MarketBeat
Is Arvinas Inc. a strong growth stockJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - 뉴스영
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Russell Investments Group Ltd. Increases Stake in Arvinas, Inc. $ARVN - MarketBeat
Nuveen LLC Buys Shares of 166,597 Arvinas, Inc. $ARVN - MarketBeat
What’s next for Arvinas Inc. stock priceJuly 2025 Sector Moves & Reliable Breakout Forecasts - Newser
Will Arvinas Inc. face regulatory challengesIndex Update & Weekly Setup with ROI Potential - خودرو بانک
Predicting Arvinas Inc. trend using moving averages2025 Trading Volume Trends & Real-Time Volume Spike Alerts - Newser
Is Arvinas Inc. stock a good dividend stockJuly 2025 Market Mood & High Accuracy Trade Alerts - خودرو بانک
How to use a screener to detect Arvinas Inc. breakoutsLayoff News & Free Weekly Chart Analysis and Trade Guides - Newser
Trend analysis for Arvinas Inc. this weekPortfolio Update Summary & Weekly Breakout Opportunity Watchlist - Newser
Analyzing Arvinas Inc. with multi timeframe chartsInflation Watch & Risk Controlled Stock Pick Alerts - Newser
Using data filters to optimize entry into Arvinas Inc.Quarterly Profit Report & AI Forecasted Entry and Exit Points - Newser
Is Arvinas Inc. building a consolidation baseShare Buyback & Free Daily Entry Point Trade Alerts - Newser
Arvinas, Inc. $ARVN Holdings Trimmed by Charles Schwab Investment Management Inc. - MarketBeat
Key metrics from Arvinas Inc.’s quarterly data2025 Top Decliners & Safe Swing Trade Setups - Newser
Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco - MSN
Statistical indicators supporting Arvinas Inc.’s strength2025 Winners & Losers & Real-Time Buy Signal Alerts - Newser
Does Arvinas Inc. offer margin of safetyQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - خودرو بانک
Arvinas to Participate in Upcoming Investor Conferences - 富途牛牛
What indicators show strength in Arvinas Inc.2025 Momentum Check & Consistent Profit Trading Strategies - Newser
How sentiment analysis helps forecast Arvinas Inc.Quarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
How to use Fibonacci retracement on Arvinas Inc.Earnings Growth Summary & Stock Portfolio Risk Control - Newser
What to expect from Arvinas Inc. in the next 30 daysStock Surge & Low Risk High Reward Trade Ideas - Newser
What Fibonacci levels say about Arvinas Inc. reboundIPO Watch & Trade Opportunity Analysis - Newser
Published on: 2025-09-02 23:09:55 - Newser
Does Arvinas Inc. meet Warren Buffett’s criteriaJuly 2025 News Drivers & Reliable Momentum Entry Alerts - خودرو بانک
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):